Естонія - естонська - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 100tk; 850mg+50mg 28tk; 850mg+50mg 196tk

Естонія - естонська - Ravimiamet

teva gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 14tk; 1000mg+50mg 98tk; 1000mg+50mg 28tk; 1000mg+50mg 60tk; 1000mg+50mg 112tk

Естонія - естонська - Ravimiamet

teva gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 28tk; 850mg+50mg 60tk; 850mg+50mg 196tk; 850mg+50mg 14tk; 850mg+50mg 112tk; 850mg+50mg 56tk; 850mg+50mg 98tk

Європейський Союз - естонська - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Європейський Союз - естонська - EMA (European Medicines Agency)

gmp-orphan sa - trientine tetrahydrochloride - hepatolentikulaarne degeneratsioon - muud alimentary seedetrakti ja ainevahetust tooted, - cuprior on näidustatud ravi wilsoni tõbi täiskasvanutel, noorukitel ja lastel ≥ 5 aastat talu, d-penitsillamiin ravi.

Європейський Союз - естонська - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Європейський Союз - естонська - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psühhoeptikumid, uinutid ja rahustid - koerad - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Європейський Союз - естонська - EMA (European Medicines Agency)

accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - opioidiga seotud häired - muud närvisüsteemi ravimid - opioidide ravivastuse asendusravi meditsiinilise, sotsiaalse ja psühholoogilise ravi raamistikus. naloksooni komponendi eesmärk on ära hoida intravenoosset väärkasutamist. ravi on ette nähtud kasutamiseks täiskasvanutel ja üle 15-aastastel noorukitel, kes on nõustunud sõltuvuse raviks.

Європейський Союз - естонська - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - kiirguse vigastused - detoxifying agents for antineoplastic treatment - lysakare on näidustatud vähendamine neeru-kiirgusega kokkupuute ajal peptiid-retseptori radionukliidide ravi (prrt) koos lutetium (177lu) oxodotreotide täiskasvanutel.

Європейський Союз - естонська - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - colesevelam (as hydrochloride) - hüperkolesteroleemia - lipiidi modifitseerivad ained - cholestagel'i koos 3-hydroxy-3-methyl-glutaryl-coenzyme-a (hmg-coa)-reduktaasi inhibiitor (statiin) on näidustatud hüperkolesteroleemiaga pakkuda madala-tihedus-lipoproteiin-kolesterooli (ldl-c) sisaldust lisaaine vähenemine primaarse hüperkolesteroleemiaga täiskasvanud patsientidel, kes ei ole adekvaatselt raviga rasvasisaldust. cholestagel nagu monotherapy on näidustatud adjunctive ravi dieedile vähendada kõrgenenud üldkolesterooli ja ldl-c täiskasvanud patsientidel, kellel on esmane hypercholesterolaemia, kellele statin loetakse sobimatuks või ei ole hästi talutav. cholestagel võib kasutada ka koos ezetimibe, koos või ilma statin, täiskasvanud patsientide esmane hypercholesterolaemia, sealhulgas patsientidel, kellel on perekondlik hypercholesterolaemia (vt lõik 5.